Uncategorized
Researchers embark on study of viral vector to treat choroideremia
A team of researchers at Bascom Palmer Eye Institute has begun a phase 2 clinical trial of a novel gene therapy designed to treat choroideremia, according to press releases from Bascom Palmer and NightstaRx.AAV2-REP1 comprises a viral vector adeno-associated virus (AAV) designed to deliver a copy of the Rab escort protein 1 (REP1) gene into the eye.